Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies

Author： Molina Rafael

Publisher： Springer Publishing Company

ISSN： 1010-4283

Source： Tumor Biology, Vol.32, Iss.1, 2011-02, pp. : 13-22

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of chromogranin A measurement in the work-up of neuroendocrine tumors

By Baudin E. Bidart J. Bachelot A. Ducreux M. Elias D. Ruffié P. Schlumberger M.

Annals of Oncology, Vol. 12, Iss. 2, 2001-02 ,pp. : 79-82

Springer Publishing Company

Access to resources Recommend Favorite

Neuroendocrine Differentiation in Renal Cell Carcinoma: Evaluation of Chromogranin A and Neuron-Specific Enolase

By Rasmuson Torgny Grankvist Kjell Roos Göran Ljungberg Börje

Acta Oncologica, Vol. 38, Iss. 5, 1999-06 ,pp. : 623-628

Informa Healthcare

Access to resources Recommend Favorite

Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience

By Stivanello M. Berruti A. Torta M. Termine A. Tampellini M. Gorzegno G. Angeli A. Dogliotti L.

Annals of Oncology, Vol. 12, Iss. 2, 2001-02 ,pp. : 73-77

Springer Publishing Company

Access to resources Recommend Favorite

Evaluation of Gefitinib for Treatment of Refractory Solid Tumors and Central Nervous System Malignancies in Pediatric Patients

By Freeman Burgess Daw Najat Geyer J. Furman Wayne Stewart Clinton

Cancer Investigation, Vol. 24, Iss. 3, 2006-05 ,pp. : 310-317

Informa Healthcare

Access to resources Recommend Favorite

New Treatment Options for Patients with Advanced Neuroendocrine Tumors

By Chan Jennifer

Current Treatment Options in Oncology, Vol. 12, Iss. 2, 2011-06 ,pp. : 136-148

Springer Publishing Company

Access to resources Recommend Favorite